- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06352541
Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo. (PRO-232)
April 9, 2024 updated by: Laboratorios Sophia S.A de C.V.
Phase I Clinical Study, Evaluating Safety and Tolerability of PRO-232 an Ophthalmic Solution, Versus Placebo, When Applied to the Ocular Surface of Ophthalmologically and Clinically Healthy Volunteers.
This is a phase I study evaluating safety and tolerability through the incidence of unexpected adverse events and IOP measurement, as well as through the incidence of stinging after its administration, compared to placebo.
Study Overview
Detailed Description
The variables to be evaluated include:
Primary (safety):
- Unexpected adverse events
- IOP
Primary (tolerability):
- Stinging
Secondary (safety):
- Expected and related adverse events
- BCVA
- Ocular surface stining
Secondary (tolerability):
- Other ocular symptoms (foreign body sensation and tearing)
The operational definition states a difference under 15% in order to consider non inferior the safety and tolerability profile of PRO-232 compared to placebo.
Study Type
Interventional
Enrollment (Estimated)
34
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Alejandra Sanchez, MD
- Phone Number: 1190 33 3001 4200
- Email: alejandra.sanchez@sophia.com.mx
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Having the ability to voluntarily give their signed informed consent.
- Ophthalmologically and clinically healthy subjects.
- Being able to and willing to comply with scheduled visits, treatment plan, and other study procedures.
- Age between 18 to 45 years.
- Male or female gender.
- Women of childbearing potential who have not undergone Bilateral Tubal Occlusion (BTO [Tubal Ligation]), hysterectomy, or bilateral oophorectomy must ensure continuation (initiated ≥ 30 days prior to signing the informed consent form [ICF]) of the use of a hormonal contraceptive method or intrauterine device (IUD) during the study period.
- Best corrected visual acuity (BCVA) of 20/30 or better in both eyes.
- Corneal staining ≤ grade I on the Oxford Scale.
- Having an intraocular pressure ≥ 10 and ≤ 21 mmHg.
Exclusion Criteria:
- History of hypersensitivity to fluoroquinolones, steroid anti-inflammatories, or any of the components of the drugs under investigation.
- Use of ophthalmic medications from any pharmacological group.
- Use of medications by any other route of administration.
- Use of non-steroidal anti-inflammatory drugs, steroid anti-inflammatory drugs, or antibiotics by any route of administration in the last 30 days.
- History of eye surgery in the last 6 months.
- Use of contact lenses for a period less than two weeks prior to the start of the study, and during the intervention period of this study.
- In the case of women: being pregnant, breastfeeding, or planning to become pregnant within the study period.
- Having participated in any clinical research study 30 days prior to inclusion in this study.
- Having previously participated in this same study.
- History of any chronic-degenerative disease, including Diabetes Mellitus or Systemic Arterial Hypertension.
- Diagnosis of glaucoma or ocular hypertension.
- Known diagnosis of liver or heart disease.
- Presenting active inflammatory or infectious disease at the time of entry into the study.
- Presenting unresolved lesions or traumas at the time of entry into the study.
- Having been subjected to non-ophthalmological surgical procedures in the last 3 months.
- Being or having an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is an employee of the research site or the sponsor, and who directly participates in this study.
- Active smoking (specified as the consumption of cigarettes regardless of the amount and frequency, 4 weeks prior to study inclusion and during the intervention period of this study).
- Active alcoholism (specified as the consumption of alcoholic beverages, regardless of the amount and frequency, 72 hours prior to study inclusion and during the intervention period of this study).
Elimination Criteria
- Withdrawal of their consent to participate in the study (informed consent form).
- Occurrence of a serious adverse event, whether related or not to the interventions, that in the opinion of the principal investigator (PI) and/or the sponsor, could affect the patient's fitness to safely continue with the study procedures.
- Non-tolerability or hypersensitivity to any of the compounds used during the tests -(fluorescein, tetracaine).
- Non-tolerability or hypersensitivity to any of the drugs under investigation.
- Adherence < 80% determined by the subject's diary and corroborated by the final weight of the research products (RP) compared to the initial weight.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PRO-232
|
Moxifloxacin 0.5% and Dexamethasone Phosphate 0.1%
|
Placebo Comparator: Placebo
|
Sodium Chloride 0.9%
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence Unexpected Related Adverse Reactions
Time Frame: Days 0 (Basal Visit) 3 (Visit 1), 8 (Final Visit) and 12 (Safety Call)
|
Any unfavorable medical condition affecting the subject after the administration of the investigation product, related to such intervention.
|
Days 0 (Basal Visit) 3 (Visit 1), 8 (Final Visit) and 12 (Safety Call)
|
Changes in intraocular pressure (IOP)
Time Frame: Days 0 (Basal Visit) 3 (Visit 1), 8 (Final Visit)
|
Previous instillation of topical anesthetic, the IOP (right eye) will be measured through a Goldmann tonometer during visits
|
Days 0 (Basal Visit) 3 (Visit 1), 8 (Final Visit)
|
Incidence of Stinging
Time Frame: Days 0 (Basal Visit, 3 (Visit 1) and 8 (Final Visit)
|
The subjects will be questioned regarding this symptom's incidence (right eye), frecuency, duration and severity will not be considered, only its incidence will.
|
Days 0 (Basal Visit, 3 (Visit 1) and 8 (Final Visit)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Expected Related Adverse Events
Time Frame: Days 0 (Basal Visit), 3 (Visit 1), 8 (Final Visit) and 12 (Safety Call)
|
Incidence of expexted related adverse events according to those previously described in bibliography: itching, blurry vision, eyelid pain, conjunctival hyperemia, ocular hypertension.
|
Days 0 (Basal Visit), 3 (Visit 1), 8 (Final Visit) and 12 (Safety Call)
|
Changes in Best Corrected Visual Acuity (BCVA)
Time Frame: Days 0 (Basal Visit), Days 3 (Visit 1) and 8 (Final Visit)
|
BCVA will be evaluated through Snellen chart
|
Days 0 (Basal Visit), Days 3 (Visit 1) and 8 (Final Visit)
|
Incidence of ocular symptoms (foreign body sensation and tearing)
Time Frame: Days 0 (Basal Visit), 3 (Visit 1), 8 (Final Visit)
|
The subjects will be questioned regarding this symptoms' incidence.
|
Days 0 (Basal Visit), 3 (Visit 1), 8 (Final Visit)
|
Changes in the integrity of the ocular surface (fluorescein staining)
Time Frame: Days 0 (Basal Visit), Days 3 (Visit 1) and 8 (Final Visit)
|
Changes in the integrity of the ocular surface using fluorescein staining and evaluated through the Oxford scale.
The standard Oxford scale for fluorescein staining has the following criteria: Grade 0- Equal to or less than panel A; Grade I- Equal to or less than panel B, greater than panel A; Grade II- Equal to or less than panel C, greater than panel B; Grade III- Equal or less than panel D, greater than panel C; Grade IV- Equal or less than panel E, greater than panel D; Grade V- Greater than panel E.
|
Days 0 (Basal Visit), Days 3 (Visit 1) and 8 (Final Visit)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 30, 2024
Primary Completion (Estimated)
June 30, 2025
Study Completion (Estimated)
June 30, 2025
Study Registration Dates
First Submitted
April 2, 2024
First Submitted That Met QC Criteria
April 2, 2024
First Posted (Actual)
April 8, 2024
Study Record Updates
Last Update Posted (Actual)
April 11, 2024
Last Update Submitted That Met QC Criteria
April 9, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- SOPH232-1122/I
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States